Patience or Denial? HIMS Drops as Red Flags Turn Real
$Hims & Hers Health Inc.(HIMS)$ – Multiple Technical and Fundamental Red Flags Ahead of Current Breakdown
Price is down -28.65% MTD, but several warning signs had already emerged since early November.
These included VARW warning, a major support break aligning with the first YoY EPS deceleration since 2022, weakening price follow-through, and a loss of the 200-MA for the first time since 2023.
Don't let patience turns into denial in a losing position.
"Hims & Hers shares fall after BofA cuts price target to $21 and flags heightened FDA-related risks to its GLP-1 business. The company is halting sales of its compounded Wegovy pill following an FDA probe and faces a $Novo-Nordisk A/S(NVO)$ federal patent-infringement lawsuit over compounded Wegovy and Ozempic products."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
